<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36485/1561-6274-2023-27-2-78-84</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-2220</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Роль склеростина в формировании сердечно-сосудистой кальцификации при хронической болезни почек С5Д</article-title><trans-title-group xml:lang="en"><trans-title>The role of sclerostin in the formation of cardiovascular calcifi cation in chronic kidney disease C5D</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1794-1830</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Махиева</surname><given-names>А. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Makhieva</surname><given-names>A. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Махиева Азиза Тахировна, аспирант</p><p>360000, г. Нальчик, ул. Чернышевского, д. 173</p><p>Тел.: +7 (866) 293 00 80, +7 (905) 439 11</p></bio><bio xml:lang="en"><p>Aziza T. Makhieva, MD</p><p>360000, Nalchik, Chernyshevsky str., 173</p></bio><email xlink:type="simple">Tm_aziza@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0378-0754</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мамбетова</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Mambetova</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мамбетова Анета Мухамедовна, проф. </p><p>360000, г. Нальчик, ул. Чернышевского, д. 173</p><p>Тел.: +7 (866) 293 00 80, +7 (905) 439 11 90</p></bio><bio xml:lang="en"><p>Aneta M. Mambetova, Prof. </p><p>360000, Nalchik, Chernyshevsky str., 173</p></bio><email xlink:type="simple">amm-0007@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кафедра общей врачебной практики, геронтологии, общественного здоровья и здравоохранения, Кабардино-Балкарский государственный университет им. Х.М. Бербекова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of General medical practice, gerontology, public health and public health, Kabardino-Balkar state University named after Kh.M. Berbekov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>07</day><month>06</month><year>2023</year></pub-date><volume>27</volume><issue>2</issue><fpage>78</fpage><lpage>84</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Махиева А.Т., Мамбетова А.М., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Махиева А.Т., Мамбетова А.М.</copyright-holder><copyright-holder xml:lang="en">Makhieva A.T., Mambetova A.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/2220">https://journal.nephrolog.ru/jour/article/view/2220</self-uri><abstract><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ: изучить взаимосвязи склеростина крови с клиническими параметрами и его влияние на вероятность обнаружения сердечно-сосудистой кальцификации у больных с ХБП С5Д.</p></sec><sec><title>ПАЦИЕНТЫ И МЕТОДЫ</title><p>ПАЦИЕНТЫ И МЕТОДЫ. Исследование одномоментное, когортное с включением 84 больных с ХБП 5Д стадии, получавших терапию гемодиализом, из них 40 (47,6, %) пациентов женского пола и 44 (52,4  %) – мужского пола. Средний возраст составил 55,6±14,9 года. Обследование включало, помимо рутинных исследований, проведение эхокардиоскопии с оценкой кальцификации клапанов сердца, рентгенографии живота в боковой проекции с оценкой кальцификации аорты, анализ показателей, характеризующих фосфорно-кальциевых обмен (уровни сывороточных склеростина, 1,25(ОН)D, FGF-23, A-klotho, паратиреоидного гормона, фосфора и кальция). Статистический анализ проводился с помощью компьютерной программы STATISTICA 12.6 (StatSoft Inc., USA).</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Было показано, что уровень склеростина выше у лиц пожилого возраста, а также у тех, кто имеет признаки гипопротеинемии и гипоальбуминемии, косвенно свидетельствующие о наличии белковоэнергетической недостаточности. Имеется связь склеростина крови с FGF-23 и Alpha-klotho. С точки зрения вероятного влияния на процессы сердечно-сосудистой кальцификации, данная связь показывает свою однонаправленность. Повышение уровня склеростина в крови ассоциировалось с риском обнаружения признаков сердечно-сосудистой кальцификации, т. е. наиболее высокий уровень склеростина в крови соответствовал наиболее выраженной степени кальцификации. Наравне с нарастанием уровня склеростина подтверждена взаимосвязь дефицита 1,25(ОН)D с сердечнососудистой кальцификацией.</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ: Высокий уровень склеростина в сыворотке крови более 92,5 пмоль/л у больных с ХБП С5Д повышает риск обнаружения признаков сердечно-сосудистой кальцификации (кальцификации стенки аорты и клапанов сердца). Повышение уровня склеростина происходит во взаимосвязи с ростом уровня FGF23 и снижением 1,25(ОН)D.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>THE AIM</title><p>THE AIM: to study the relationship of blood sclerostin with clinical parameters and its influence on the probability of detection of cardiovascular calcification in patients with CKD C5D.</p></sec><sec><title>PATIENTS AND METHODS</title><p>PATIENTS AND METHODS. The study was a single-stage, cohort study involving 84 patients with stage 5D CKD who received hemodialysis therapy, including 40 (47.6 %) female patients and 44 (52.4 %) male patients. The average age was 55.6±14.9 years. The examination included, in addition to routine studies, echocardioscopy with an assessment of calcification of the heart valves, abdominal radiography in the lateral projection with an assessment of aortic calcification, analysis of indicators that characterize phosphorus-calcium metabolism (serum sclerostin levels, 1.25(OH)D, FGF-23, A-klotho, PTH, P and Cа blood). Statistical analysis was performed using the computer program STATISTICA 12.6 (StatSoft Inc., USA).</p></sec><sec><title>RESULTS</title><p>RESULTS. It was shown that the level of sclerostin is higher in the elderly, as well as those who have signs of hypoproteinemia and hypoalbuminemia, indirectly indicating the presence of protein-energy deficiency. There is an Association of blood sclerostin with FGF-23 and Alpha-klotho. From the point of view of the probable influence on the processes of cardiovascular calcification, this relationship shows its unidirectionality. Increased blood sclerostin levels have been shown to be associated with the risk of detecting signs of cardiovascular calcification. Moreover, it is shown that the higher the level of sclerostin in the blood, the more pronounced the degree of this calcification. Along with the increase in the level of sclerostin, the ability of a deficit of 1.25(OH)D to lead to the development of calcification was confirmed.</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION. A high level of sclerostin in the blood serum of more than 92.5 pmol / l in patients with CKD C5D increases the risk of detecting signs of cardiovascular calcification (calcification of the aortic wall and heart valves). An increase in sclerostin levels occurs in conjunction with an increase in FGF-23 and a decrease in 1.25(OH)D</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>склеростин</kwd><kwd>хроническая болезнь почек</kwd><kwd>сердечно-сосудистая кальцификация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>sclerostin</kwd><kwd>chronic kidney disease</kwd><kwd>cardiovascular calcification</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Tuot DS, McCulloch CE, Velasquez A et al. Impact of a Primary Care CKD Registry in a US Public Safety-Net Health Care Delivery System: A Pragmatic Randomized Trial. Am J Kidney Dis 2018;72(2):168–177. doi: 10.1053/j.ajkd.2018.01.058</mixed-citation><mixed-citation xml:lang="en">Tuot DS, McCulloch CE, Velasquez A et al. Impact of a Primary Care CKD Registry in a US Public Safety-Net Health Care Delivery System: A Pragmatic Randomized Trial. Am J Kidney Dis 2018;72(2):168–177. doi: 10.1053/j.ajkd.2018.01.058</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Шутов ЕВ. Новые подходы к лечению ХБП. Московская медицина 2016;12:209</mixed-citation><mixed-citation xml:lang="en">Shutov EV. New approaches to the treatment of CKD. Moscow medicine 2016;12:209 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Андрусев АМ, Перегудова НГ, Шинкарев МБ, Томилина НА. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации 20142018 гг. Регистр заместительной почечной терапии Российского диализного общества. Общероссийская Общественная Организация Нефрологов «Российское Диализное Общество» 2019:16. http://webmed.irkutsk.ru/doc/pdf/tkfru.pdf</mixed-citation><mixed-citation xml:lang="en">Andrusev AM, Peregudova NG, Shinkarev MB, Tomilina NA. Replacement therapy for end-stage chronic kidney failure in the Russian Federation 2014-2018 Register of renal replacement therapy of the Russian dialysis society. All-Russian Public Organization Of Nephrologists "Russian Dialysis Society" 2019:16. http://webmed.irkutsk.ru/doc/pdf/tkfru.pdf (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Строков АГ, Гуревич КЯ, Ильин АП и соавт. Лечение пациентов с хронической болезнью почек 5 стадии (ХБП 5) методами гемодиализа и гемодиафильтрации. Клинические рекомендации. Нефрология 2017;21(3):92–111. doi: 10.24884/1561-6274-2017-3-92-111</mixed-citation><mixed-citation xml:lang="en">Strokov AG, Gurevich KY, Ilyin AP et al. Treatment of patients with stage 5 chronic kidney disease (CKD 5) by hemodialysis and hemodiafiltration. Clinical recommendations. Nephrology (SaintPetersburg). 2017;21(3):92–111 (In Russ.). doi: 10.24884/1561-6274-2017-3-92-111</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Вишневский КА, Земченков АЮ, Герасимчук РП и соавт. Фармакоэкономика лечения МКН-ХБП: обзор литературы. Нефрология 2018;22(1):38–51. doi: 10.24884/1561-6274-2018-22-1-38-51</mixed-citation><mixed-citation xml:lang="en">Vishnevsky KA, Zemchenkov AU, Gerasimchuk RP et al. Pharmacoeconomics of treatment of MKN-CKD: review of the literature. Nephrology (Saint-Petersburg) 2018;22(1):38–51. (In Russ.). doi: 10.24884/1561-6274-2018-22-1-38-51</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ocak G, Noordzij M, Rookmaaker MB et al. Mortality due to bleeding, myocardial infarction and stroke in dialysis patients. J Thromb Haemost 2018;16(10):1953–1963. doi: 10.1111/jth.14254</mixed-citation><mixed-citation xml:lang="en">Ocak G, Noordzij M, Rookmaaker MB et al. Mortality due to bleeding, myocardial infarction and stroke in dialysis patients. J Thromb Haemost 2018;16(10):1953–1963. doi: 10.1111/jth.14254</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Руденко ЛИ, Батюшин ММ, Кастанаян АА, Воробьев БИ. Прогнозирование риска развития кардио-васкулярной кальцификации у пациентов, получающих хронический гемодиализ. Нефрология 2015;19(5):72–76</mixed-citation><mixed-citation xml:lang="en">Rudenko LI, Batiushin MM, Castanayan AA, Vorobiev BI. Predicting the risk of cardio-vascular calcification in patients receiving chronic hemodialysis. Nephrology (Saint-Petersburg) 2015;19(5):72–76 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kramer I, Halleux C, Keller H et al. Osteocyte Wnt/{beta}- catenin signaling is required for normal bone homeostasis. Mol Cell Biol 2010;30:3071–3085. doi: 10.1128/MCB.01428-09</mixed-citation><mixed-citation xml:lang="en">Sugatani T. Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder. Int J Mol Sci 2018;19(9):2490.  doi: 10.3390/ijms19092490</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Милованова ЛЮ, Козловская ЛВ, Милованова СЮ и др. Взаимосвязь фактора роста фибробластов-23 (FGF-23) SKLOTHO, тропонина-I у больных хронической болезнью почек. Международный научно-исследовательский журнал 2016;51(9-3):65–69. doi: 10.18454/IRJ.2016.51.074</mixed-citation><mixed-citation xml:lang="en">Kramer I, Halleux C, Keller H et al. Osteocyte Wnt/{beta}- catenin signaling is required for normal bone homeostasis. Mol Cell Biol 2010;30:3071–3085. doi: 10.1128/MCB.01428-09</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sato M, Hanafusa N, Kawaguchi H et al. A Prospective Cohort Study Showing No Association Between Serum Sclerostin Level and Mortality in Maintenance Hemodialysis Patients. Kidney Blood Press Res 2018;43(3):1023–1033. doi: 10.1159/000490824</mixed-citation><mixed-citation xml:lang="en">Milovanova LU, Kozlovskaya LV, Milovanova SU et al. Relationship of fibroblast growth factor-23 (FGF-23) KLOTHO and troponin-I in patients with chronic kidney disease. International research journal 2016;51(9-3):65–69 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Dam M, Neelemaat F, Struijk-Wielinga T et al. Physical Performance and Protein-Energy Wasting in Patients Treated With Nocturnal Haemodialysis Compared to Conventional Haemodialysis: Protocol of the DiapriFIT Study. BMC Nephrol 2017;18(1):144. doi: 10.1186/s12882-017-0562-1</mixed-citation><mixed-citation xml:lang="en">Sato M, Hanafusa N, Kawaguchi H et al. A Prospective Cohort Study Showing No Association Between Serum Sclerostin Level and Mortality in Maintenance Hemodialysis Patients. Kidney Blood Press Res 2018;43(3):1023–1033. doi: 10.1159/000490824</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mödder UI, Hoey KA, Amin S et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011;26:373-379. doi: 10.1002/jbmr.217</mixed-citation><mixed-citation xml:lang="en">Dam M,  Neelemaat F,  Struijk-Wielinga T et al. Physical Performance and Protein-Energy Wasting in Patients Treated With Nocturnal Haemodialysis Compared to Conventional Haemodialysis: Protocol of the DiapriFIT Study. BMC Nephrol 2017;18(1):144. doi: 10.1186/s12882-017-0562-1</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Unver S, Kavlak E, Gümüsel HK et al. Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients. Ren Fail 2015;37:951–956. doi: 10.3109/0886022X.2015.1052945</mixed-citation><mixed-citation xml:lang="en">Mödder UI, Hoey KA, Amin S et al. Relation of  age, gender, and bone mass to circulating sclerostin  levels in  women and men. J Bone Miner Res 2011;26:373-379. doi: 10.1002/jbmr.217</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Unver S, Kavlak E, Gümüsel HK et al. Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients. Ren Fail 2015;37:951–956. doi: 10.3109/0886022X.2015.1052945</mixed-citation><mixed-citation xml:lang="en">Unver S, Kavlak E, Gümüsel HK et al. Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients. Ren Fail 2015;37:951–956. doi: 10.3109/0886022X.2015.1052945</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
